Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"DCVC Bio","pharmaFlowCategory":"D","amount":"$33.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novome Biotechnologies Raises $33 Million Series A Financing and Appoints Blake Wise as Chief Executive Officer","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved"},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$605.0 million","upfrontCash":"$15.0 million","newsHeadline":"Novome Biotechnologies and Genentech Enter into a Strategic Collaboration to Develop Targets Against Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Tencent","pharmaFlowCategory":"D","amount":"$43.5 million","upfrontCash":"Undisclosed","newsHeadline":"Novome Biotechnologies Raises $43.5 Million Series B Financing to Advance its Pipeline of Therapeutically Engineered Microbes","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Novome Biotechnologies

    Menu

    Novome Biotechnologies

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Novome Biotechnologies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Novome Biotechnologies Raises $43.5 Million Series B Financing to Advance its Pipeline of Therapeutically Engineered Microbes

              Details:

              The proceeds will be used to advance both Novome’s clinical hyperoxaluria candidate, NOV001, through an ongoing Phase 2a clinical trial and multiple Genetically Engineered Microbial Medicines (GEMMs) candidates for the potential treatment of inflammatory bowel disease (IBD).

              Lead Product(s): NB1000S,NB2000P

              Therapeutic Area: Gastroenterology Product Name: NOV-001

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Tencent

              Deal Size: $43.5 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing September 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Novome Biotechnologies

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001

              Details:

              NOV-001 is an investigational combination product composed of NB1000S and NB2000P. Preclinical studies of NOV001 showed consistent and robust reduction in urine oxalate levels in multiple animal models of disease.

              Lead Product(s): NB1000S,NB2000P

              Therapeutic Area: Gastroenterology Product Name: NOV-001

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 17, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Novome Biotechnologies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Novome Biotechnologies and Genentech Enter into a Strategic Collaboration to Develop Targets Against Inflammatory Bowel Disease

              Details:

              Under the terms of the agreement, Novome will have responsibility for research activities up to initiation of IND-enabling preclinical studies for this multi-target collaboration.

              Lead Product(s): Genetically Engineered Microbial Medicines

              Therapeutic Area: Gastroenterology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Genentech

              Deal Size: $605.0 million Upfront Cash: $15.0 million

              Deal Type: Collaboration November 10, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Novome Biotechnologies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Novome Biotechnologies Raises $33 Million Series A Financing and Appoints Blake Wise as Chief Executive Officer

              Details:

              The financing will be used to advance the company’s lead hyperoxaluria program through Phase 1 clinical proof-of-concept work, as well as to expand its (GEMMs) platform.

              Lead Product(s): Undisclosed

              Therapeutic Area: Nephrology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: DCVC Bio

              Deal Size: $33.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing January 07, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY